Related references
Note: Only part of the references are listed.Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)
Ying Zhu et al.
JOURNAL OF INFECTION (2020)
COVID-19 Autopsies, Oklahoma, USA
Lisa M. Barton et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2020)
CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19 Definition and Evaluation
Mathias Prokop et al.
RADIOLOGY (2020)
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
Mengyuan Dai et al.
CANCER DISCOVERY (2020)
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Jia Luo et al.
CANCER DISCOVERY (2020)
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care
Angelo Dipasquale et al.
FRONTIERS IN ONCOLOGY (2020)
Moving towards personalized treatments of immune-related adverse events
Khashayar Esfahani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks
Salvatore Crisafulli et al.
BIODRUGS (2020)
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management
Marco Russano et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Thilo Gambichler et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Determinants of COVID-19 disease severity in patients with cancer
Elizabeth V. Robilotti et al.
NATURE MEDICINE (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity
James Lyons-Weiler
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2020)
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
Michele Porcu et al.
CANCERS (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
Jonathan D. Schoenfeld et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature
Farkhad Manapov et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
Osamu Kanai et al.
THORACIC CANCER (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Share Paper
